\
&
Contact us
\
&
Contact us
Published on | 6 months ago
ProgrammesThe European Commission has launched a Call for Expression of Interest to recruit up to six new Programme Managers of the European Innovation Council (EIC) - Europe's flagship innovation programme to identify, develop and scale up game changing innovations- and to establish a reserve list for future opportunities.
As an EIC Programme Manager you will oversee a thematic portfolio, set ambitious technology visions, identify future trends, and support EIC beneficiaries on their innovation journey. The current call is open to top-level experts with strong scientific, technological, or innovation experience in any deep-tech field.
Successful candidates will join a dynamic team of Programme Managers who each lead portfolios in strategically important areas. The role involves setting ambitious technology goals, anticipating emerging trends, and proactively supporting the journey from cutting-edge research to transformative innovation outcomes.
All details of the vacancy notice are available on the EIC website. Deadline for applications: 26 September 2025 at 12:00 (Brussels time).
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
